The Cardionomic team has demonstrated high levels of capital efficiency in developing this breakthrough therapy and expects to demonstrate similar success moving forward.

Cardionomic successfully completed a $20M Series A Round funding in October of 2015.

The company’s primary patents have been issued (8,798,738; 8,818,501; 8,818,501; 8,798,738; 9,480,790; 9,878,150

7,532,938; 7,865,237; 11201608878S; 3,194,007B1.) Cardionomic continues to develop an extensive portfolio covering all aspects of the system.

Primary Patents